Cu-64-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor

摘要

This purpose of this study is to determine the efficacy of a 45 amino acid Gp2 domain, engineered to bind to epidermal growth factor receptor (EGFR), as a positron emission tomography (PET) probe of EGFR in a xenograft mouse model. The EGFR-targeted Gp2 (Gp2-EGFR) and a nonbinding control were site-specifically labeled with 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid (DOTA) chelator. Binding affinity was tested toward human EGFR and mouse EGFR Biological activity on downstream EGFR signaling was examined in cell culture. DOTA-Gp2 molecules were labeled with Cu-64 and intravenously injected (0.6-2.3 MBq) into mice bearing EGFR(high) (n = 7) and EGFR(low) (n = 4) xenografted tumors. PET/computed tomography (CT) images were acquired at 45 min 2 h, and 24 h. Dynamic PET (25 min) was also acquired. Tomography results were verified with gamma counting of resected tissues. Two-tailed t tests with unequal variances provided statistical comparison. DOTA-Gp2-EGFR bound strongly to human (K-D = 7 +/- 5 nM) and murine (K-D = 29 +/- 6 nM) EGFR, and nontargeted Gp2 had no detectable binding. Gp2-EGFR did not agonize EGFR nor antagonize EGF-EGFR. Cu-64-Gp2-EGFR tracer effectively localized to EGFR(high) tumors at 45 min (3.2 +/- 0.5%ID/g). High specificity was observed with significantly lower uptake in EGFR(low) tumors (0.9 +/- 0.3%ID/g, p < 0.001), high tumor-to-background ratios (11 +/- 6 tumor/muscle, p < 0.001). Nontargeted Gp2 tracer had low uptake in EGFR(high) tumors (0.5 +/- 0.3%ID/g, p < 0.001). Similar data was observed at 2 h, and tumor signal was retained at 24 h (2.9 +/- 0.3%ID/g). An engineered Gp2 PET imaging probe exhibited low background and target-specific EGFR(high) tumor uptake at 45 min, with tumor signal retained at 24 h postinjection, and compared favorably with published EGFR PET probes for alternative protein scaffolds. These beneficial in vivo characteristics, combined with thermal stability, efficient evolution, and small size of the Gp2 domain validate its use as a future class of molecular imaging agents.